Clinical trial Recruiting at 1 site Interventional Ages 18 and up Women only

Isokinetic microdose exercise for women with fibromyalgia

Official title: Effects of a Microdoses Isokinetic Exercise Protocol in Women With Fibromyalgia

Run by European University Miguel de Cervantes · NCT07483216 · Data updated 2026-11-12

This 8-week program will test whether low-dose isokinetic exercise helps women with fibromyalgia reduce pain, improve strength, and enhance quality of life.

Quick facts

Study typeInterventional
Ages18 Years and up
SexWomen only
Enrollment36 (estimated)
SponsorEuropean University Miguel de Cervantes
Academic / other
Locations1 site (Valladolid, Valladolid)
StatusRecruiting
StartedApril 2026
Main results expectedJuly 2026
Study endsJuly 2026
Registry record updatedApril 16, 2026
Trial IDNCT07483216 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adult women diagnosed with fibromyalgia who are clinically and pharmacologically stable and able to perform supervised exercise sessions are the ideal candidates.

Probably not a fit

Men, people with unstable medical conditions or cardiovascular/neurologic/musculoskeletal contraindications to exercise, or those unable to attend supervised sessions are unlikely to receive benefit from participating.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study enrolls adult women with a clinical diagnosis of fibromyalgia to receive an 8-week supervised isokinetic exercise program delivered using microdosing principles to limit intensity and volume. Isokinetic equipment will control movement velocity and joint position to enable safe, precisely dosed muscle contractions. Researchers will measure physical condition (including strength and function), perceived pain, inflammatory biomarkers, and quality of life before and after the intervention. Participants must be clinically and pharmacologically stable and able to attend supervised sessions at the study site.

Why it matters

Potential benefit: If successful, this approach could provide a low-intensity, better-tolerated exercise option that reduces pain and improves strength and daily functioning for women with fibromyalgia.

How similar studies have gone: General exercise programs have demonstrated benefits in fibromyalgia, but isokinetic microdosing is a relatively novel approach with limited prior clinical data.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Women aged ≥ 18 years diagnosed with fibromyalgia according to current clinical criteria.
* Clinical and pharmacological stability during the weeks prior to participation in the study.
* Ability to perform supervised exercise and to complete the assessments.
* Written informed consent.

Exclusion Criteria:

* Cardiovascular, neurologic, musculoskeletal or systemic pathology that contraindicate the performance of exercise.
* Significant change in pharmacological treatment during the period immediately preceding the study.
* Any condition that, in clinical judgement, prevents them from following the protocol safely.

Where it's running

  • Miguel de Cervantes European University
    Valladolid, Valladolid, Spain
    Recruiting

Study contacts

  • Principal investigator: Alejandro Santos Lozano, PhD — Miguel de Cervantes European University
  • Study coordinator: Alejandro Santos Lozano, PhD
  • Email: asantos@uemc.es
  • Phone: 0034983001000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.